阿利西尤单抗对冠状动脉旁路移植术后心血管事件的影响
ODYSSEY OUTCOMES预设分析纳入18,924例近期急性冠脉综合征且接受高强度他汀后致动脉粥样硬化脂蛋白仍升高的患者,随机接受阿利西尤单抗或安慰剂,中位随访2.8年。在急性冠脉综合征前已有CABG的患者中,阿利西尤单抗与MACE和死亡的绝对风险大幅降低相关。
要点
- ACS前有CABG者,阿利西尤单抗降低MACE的HR为0.77(95%CI 0.61–0.98)。
- 该亚组MACE绝对风险降低6.4%(95%CI 0.9%–12.0%),死亡绝对风险降低3.6%(95%CI 0.0%–7.2%)。
- 各CABG类别的HR与总体试验结果一致。
核心结论
- 在近期ACS且高强度他汀治疗后致动脉粥样硬化脂蛋白仍升高的患者中,阿利西尤单抗使ACS前有CABG者MACE和死亡绝对风险大幅降低。
研究设计与样本
- ODYSSEY OUTCOMES预设分析,纳入18,924例ACS后1–12个月且高强度他汀治疗后致动脉粥样硬化脂蛋白升高的患者,随机接受阿利西尤单抗或安慰剂皮下注射每2周一次,中位随访2.8年。
主要发现
- MACE的HR(95%CI):无CABG 0.86(0.78–0.95),ACS后随机前CABG 0.85(0.54–1.35),ACS前CABG 0.77(0.61–0.98)。
- 死亡的HR(95%CI):无CABG 0.88(0.75–1.03),ACS后随机前CABG 0.85(0.46–1.59),ACS前CABG 0.67(0.44–1.01)。
- MACE绝对风险降低(95%CI):无CABG 1.3%(0.5%–2.2%),ACS后随机前CABG 0.9%(-2.3%–4.0%),ACS前CABG 6.4%(0.9%–12.0%)。
- 死亡绝对风险降低(95%CI):无CABG 0.4%(-0.1%–1.0%),ACS后随机前CABG 0.5%(-1.9%–2.9%),ACS前CABG 3.6%(0.0%–7.2%)。
- 总体试验MACE的HR为0.85(0.78–0.93),死亡的HR为0.85(0.73–0.98)。
临床怎么用
- 对近期ACS且高强度他汀治疗后致动脉粥样硬化脂蛋白仍升高、ACS前有CABG病史的患者,可考虑加用阿利西尤单抗以降低MACE和死亡风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients with acute coronary syndrome (ACS) and history of coronary artery bypass grafting (CABG) are at high risk for recurrent cardiovascular events and death. OBJECTIVES: This study sought to determine the clinical benefit of adding alirocumab to statins in ACS patients with prior CABG in a pre-specified analysis of ODYSSEY OUTCOMES (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab). METHODS: Patients (n = 18,924) 1 to 12 months post-ACS with elevated atherogenic lipoprotein levels despite high-intensity statin therapy were randomized to alirocumab or placebo subcutaneously every 2 weeks. Median follow-up was 2.8 years. The primary composite endpoint of major adverse cardiovascular events (MACE) comprised coronary heart disease death, nonfatal myocardial infarction, ischemic stroke, or unstable angina requiring hospitalization. All-cause death was a secondary endpoint. Patients were categorized by CABG status: no CABG (n = 16,896); index CABG after qualifying ACS, but before randomization (n = 1,025); or CABG before the qualifying ACS (n = 1,003). RESULTS: In each CABG category, hazard ratios (95% confidence intervals) for MACE (no CABG 0.86 [0.78 to 0.95], index CABG 0.85 [0.54 to 1.35], prior CABG 0.77 [0.61 to 0.98]) and death (0.88 [0.75 to 1.03], 0.85 [0.46 to 1.59], 0.67 [0.44 to 1.01], respectively) were consistent with the overall trial results (0.85 [0.78 to 0.93] and 0.85 [0.73 to 0.98], respectively). Absolute risk reductions (95% confidence intervals) differed across CABG categories for MACE (no CABG 1.3% [0.5% to 2.2%], index CABG 0.9% [-2.3% to 4.0%], prior CABG 6.4% [0.9% to 12.0%]) and for death (0.4% [-0.1% to 1.0%], 0.5% [-1.9% to 2.9%], and 3.6% [0.0% to 7.2%]). CONCLUSIONS: Among patients with recent ACS and elevated atherogenic lipoproteins despite intensive statin therapy, alirocumab was associated with large absolute reductions in MACE and death in those with CABG preceding the ACS event. (ODYSSEY OUTCOMES: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab; NCT01663402).
引用
- Goodman SG, Aylward PE, Szarek M, et al. Effects of Alirocumab on Cardiovascular Events After Coronary Bypass Surgery. J Am Coll Cardiol. 2019. PMID: 31466614. doi:10.1016/j.jacc.2019.07.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。